Use of oral bisphosphonates and bone mineral density changes in moderate-severe (Stage 3B+) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark
In addition to safety concerns, there is a paucity of data for oral bisphosphonates (oBP) to improve bone mineral density (BMD) in patients with moderate or severe chronic kidney disease (CKD). We linked all BMD measurements in the Funen area (pop 478,000, Denmark) to biochemistry, national health...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
Wiley
2017
|